Eli Lilly, Virbac Group deal

Eli Lilly will divest to Virbac major veterinary products marketed in the U.S. by the Novartis Animal Health division of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) in connection with the U.S. Federal Trade Commission's review of Lilly's pending acquisition of the division. The completion of this transaction is subject to approval by the Federal Trade Commission, which Virbac says it expects in the near future, following the close of Lilly's acquisition of the division. The companies declined to provide financial terms. ...